Akorn Stock Price, Forecast & Analysis (NASDAQ:AKRX)

Akorn trades on the NASDAQ under the ticker symbol "AKRX."

Akorn, Inc. (NASDAQ:AKRX) announced its quarterly earnings results on Thursday, October, 31st. The company reported $0.02 EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.04) by $0.06. The business had revenue of $176.24 million for the quarter, compared to analyst estimates of $176.15 million. Akorn had a negative return on equity of 19.95% and a negative net margin of 53.62%. The company's quarterly revenue was up 6.4% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.06) EPS. View Akorn's Earnings History.

4 brokers have issued 1-year price objectives for Akorn's stock. Their forecasts range from $4.00 to $11.00. On average, they anticipate Akorn's stock price to reach $7.00 in the next year. This suggests a possible upside of 67.5% from the stock's current price. View Analyst Price Targets for Akorn.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akorn in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akorn.

Headlines about AKRX stock have been trending very negative this week, InfoTrie reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Akorn earned a media sentiment score of -3.2 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Akorn.

Akorn saw a drop in short interest in October. As of October 31st, there was short interest totalling 9,280,000 shares, a drop of 15.0% from the September 30th total of 10,920,000 shares. Based on an average trading volume of 1,970,000 shares, the days-to-cover ratio is currently 4.7 days. Approximately 9.9% of the company's shares are short sold. View Akorn's Current Options Chain.

Some companies that are related to Akorn include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Allergan (AGN), Zoetis (ZTS), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Horizon Therapeutics (HZNP), The Medicines (MDCO), Nektar Therapeutics (NKTR) and Zogenix (ZGNX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Akorn investors own include Celgene (CELG), Integrated Device Technology (IDTI), Skechers USA (SKX), Rite Aid (RAD), Lannett (LCI), Bank of America (BAC), Quantenna Communications (QTNA), Ulta Beauty (ULTA), Paycom Software (PAYC) and Square (SQ).

Akorn's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Mackay Shields LLC (0.57%), Gabelli Funds LLC (0.35%), Gamco Investors INC. ET AL (0.29%), Rhumbline Advisers (0.23%), Assenagon Asset Management S.A. (0.18%) and California Public Employees Retirement System (0.11%). Company insiders that own Akorn stock include Alan D Weinstein, Brian Tambi, John N Kapoor, Joseph Bonaccorsi, Steven J Meyer and Terry Allison Rappuhn. View Institutional Ownership Trends for Akorn.

AKRX stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., SG Americas Securities LLC, Chicago Equity Partners LLC and Gabelli Funds LLC. View Insider Buying and Selling for Akorn.

AKRX stock was purchased by a variety of institutional investors in the last quarter, including Mackay Shields LLC, Tibra Equities Europe Ltd, State of Alaska Department of Revenue, Nisa Investment Advisors LLC, Gamco Investors INC. ET AL, California Public Employees Retirement System, Rhumbline Advisers and Moors & Cabot Inc.. Company insiders that have bought Akorn stock in the last two years include Alan D Weinstein, Joseph Bonaccorsi, Steven J Meyer and Terry Allison Rappuhn. View Insider Buying and Selling for Akorn.

Shares of AKRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AKRX stock can currently be purchased for approximately $4.18.

Akorn has a market capitalization of $527.29 million and generates $694.02 million in revenue each year. The company earns $-401,910,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Akorn employs 2,191 workers across the globe.View Additional Information About Akorn.

The official website for Akorn is http://www.akorn.com/.

Akorn's mailing address is 1925 WEST FIELD COURT SUITE 300, LAKE FOREST IL, 60045. The company can be reached via phone at 847-279-6100 or via email at [email protected]